CAP-Ketamine for Antidepressant Resistant PTSD
Launched by VA OFFICE OF RESEARCH AND DEVELOPMENT · Jan 11, 2016
Trial Information
Current as of September 29, 2025
Completed
Keywords
ClinConnect Summary
In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants receive the study drug via intravenous infusion twice per week for 4-weeks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • male or female Veterans or active duty military personnel between the ages of 18 and 70 years
- • diagnosis of PTSD
- • history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
- • ability to provide written informed consent
- Exclusion Criteria:
- • females who are currently pregnant or breastfeeding
- • current high risk for suicide
- • history of severe head injury
About Va Office Of Research And Development
The VA Office of Research and Development (ORD) is dedicated to advancing the health and well-being of veterans through innovative research initiatives. As a pivotal sponsor of clinical trials, ORD focuses on a broad spectrum of health-related topics, including mental health, rehabilitation, and chronic disease management, ensuring that findings are directly applicable to the unique needs of the veteran population. With a commitment to scientific excellence and collaboration, ORD promotes rigorous study designs and ethical standards, facilitating the translation of research discoveries into improved clinical practices and policies that enhance veteran care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
West Haven, Connecticut, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
John H. Krystal, MD
Principal Investigator
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials